SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Last trade$2.92
Day change-$0.08 (-2.67%)
Day range$2.83 – $3.07
Volume151,338
Market cap$270M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$270.27M
Price / earnings
—
Price / book
1.28×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.16×
Profitability
Earnings per share
-$0.74
Return on assets
-28.22%
Return on equity
-31.53%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
7.28×
Quick ratio
7.28×
Cash ratio
0.98×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$58.76M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SABS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$114.7K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$114.7K
Selling, general and administrative
$7.82M
$7.21M
$6.6M
$5.04M
$3.71M
$2.74M
$3.11M
$2.47M
Research and development
$18.08M
$16.17M
$13.4M
$10.73M
$8.97M
$7M
$7.66M
$7.65M
Total operating expenses
$25.9M
$23.38M
$20M
$15.77M
$12.68M
$9.73M
$10.77M
$10.12M
Operating income
-$25.9M
-$23.38M
-$20M
-$15.77M
-$12.68M
-$9.73M
-$10.77M
-$10.01M
Interest expense
$0
-$62K
-$62.75K
-$63.46K
$0
-$64K
-$69.57K
-$70.88K
Income before taxes
-$22.3M
-$22.49M
-$18.87M
-$16.86M
$45.45M
-$10.11M
-$5.2M
-$11.39M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$22.3M
-$22.49M
-$18.87M
-$16.86M
$45.45M
-$10.11M
-$5.2M
-$11.39M
Net income attributable to common shareholders
-$22.3M
-$22.49M
-$18.87M
-$2.85M
$5.34M
-$10.11M
-$5.2M
-$11.39M
EBITDA
-$25.1M
-$22.56M
-$19.27M
-$15.01M
-$11.94M
-$8.98M
-$10.02M
-$9.22M
Basic earnings per share
-$0.24
-$0.28
-$0.35
-$0.06
$0.50
-$1.09
-$0.56
-$1.23
Diluted earnings per share
-$0.24
-$0.28
-$0.35
-$0.02
-$0.21
-$1.09
-$0.56
-$1.23
Recent news
Company coverage with links to the original publishers.
SAB Biotherapeutics announced the pricing of an $85 million public offering consisting of 19.3 million shares at $3.85 per share and pre-funded warrants. The company plans to use proceeds to fund development of SAB-142, its clinical-stage candidate for type 1 diabetes, through ongoing Phase 2b trials and related activities. The offering is expected to close on March 19, 2026.
SAB Biotherapeutics (Nasdaq: SABS) announced a public offering of 19.3 million shares at $3.85 per share and 2.75 million pre-funded warrants, expected to raise approximately $85 million in gross proceeds. The company plans to use the funds to advance development of SAB-142, its lead candidate for type 1 diabetes, through ongoing clinical trials and related activities.
SAB Biotherapeutics announced that its management team will participate in two investor conferences in February 2026: the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. The company is developing SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes treatment.
SAB Biotherapeutics announced the appointment of David Zaccardelli, Pharm.D. as Board Chair and Rita Jain, M.D. as an independent director, effective immediately. Zaccardelli brings over 20 years of biopharmaceutical executive experience, including leading the successful launch of Ohtuvayre® at Verona Pharma. Jain is a rheumatologist with two decades of experience in biopharmaceutical development and clinical strategy. Both appointments are intended to support the company's advancement of SAB-142, its lead candidate for Type 1 Diabetes treatment, through clinical development and potential commercialization.
SAB Biotherapeutics reported positive Phase 1 trial results for SAB-142, a potential treatment for type 1 diabetes, demonstrating safety, low immunogenicity, and no serum sickness across healthy volunteers and patients.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.